Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02162 KEYMED BIO-B > Detailed Quotes

02162 KEYMED BIO-B

Watchlist
52.200
+3.200+6.53%
Trading Session  12/09 13:14 CCT
High
52.500
Open
48.950
Turnover
24.03M
Low
48.500
Pre Close
49.000
Volume
474.50K
Market Cap
14.60B
P/E(TTM)
Loss
52wk High
57.950
Shares
279.74M
P/E(Static)
Loss
52wk Low
16.900
Float Cap
14.60B
Bid/Ask %
-79.80%
Historical High
79.800
Shs Float
279.74M
Volume Ratio
1.24
Historical Low
16.900
Dividend TTM
--
Div Yield TTM
--
P/B
3.43
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.17%
Amplitude
8.16%
Avg Price
50.650
Lot Size
500
Float Cap
14.60B
Bid/Ask %
-79.80%
Historical High
79.800
Shs Float
279.74M
Volume Ratio
1.24
Historical Low
16.900
Dividend TTM
--
P/B
3.43
Dividend LFY
--
Turnover Ratio
0.17%
Amplitude
8.16%
Avg Price
50.650
Lot Size
500
Price Forecast

News

Comment

Company Overview More
Konoya Biopharmaceutical Technology Co., Ltd. is a biotechnology company with a variety of clinical assets, each of which is a strong competitor in its respective competitive field. We focus on finding and developing innovative biotherapies to meet a large number of unmet medical needs in the field of autoimmunity and oncology therapy. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development technologies, including our innovative antibody discovery platform and our own novel T cell redirection (nTCE) bispecific antibody platform. In less than five years since its establishment, we have consistently explored areas of disease treatment that are extremely challenging and in short supply. Now, we have more than ten drug candidates in the internal development stage, five of which are in the clinical stage. Our own products under research and development apply cutting-edge scientific discoveries and reflect our profound market insight. Health spending increased significantly in the first two decades of the new millennium driven by economic growth and the reform of the health care system. Due to the rapid development of urbanization, changes in residents' lifestyle and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends pose new challenges to public health and expose new areas of disease that are heavily burdened by inadequate treatments. To support our innovative research and development of biopharmaceuticals, we have established a fully integrated platform covering all key functions of biopharmaceutical development, including target verification, lead compound generation and optimization, preclinical evaluation, process development, transformation research, clinical development and production. This integrated platform enables us to quickly and cost-effectively discover, build, expand and advance our diversified pipeline of innovative and differentiated antibody therapy, including monoclonal antibodies, antibody-coupled drugs and bispecific antibodies.
CEO: Bo CHEN
Market: Hong Kong motherboard
Listing Date: 07/08/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist